Fig. 3From: Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinomaThe cost-effectiveness acceptability curves for nivolumab plus ipilimumab strategy compared to the sunitinib strategy in three countriesBack to article page